English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12145/12927 (94%)
造訪人次 : 857826      線上人數 : 835
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/9215


    題名: Randomized, phase III trial of adjuvant adeforvir vs. therapeutic lamivudine in post-operative BCLC stage 0 or A HBV-related HCC: The Taiwan Cooperative Oncology Group T1206 study
    作者: Chen, LT;Jeng, LB;Hsiao, CF;Wu, CC;Lee, WC;Wang, TE;Lee, PH;Chen, CL;Chen, IS;Lee, KT;Hsieh, CB;Hwang, WS;Yang, MD;Yang, YS;Lin, DY;Chen, MF;Chen, PJ;Taiwan Cooperative Oncology, G
    貢獻者: National Institute of Cancer Research;Division of Clinical Trial Statistics
    摘要: Background: To investigate the role of adjuvant anti-viral nucleoside in tertiary prevention of HCC relapse in post-operative BCLC stage 0 or A HBV-related HCC. Methods: Patients with curative resection of BCLC stage 0 or A and solitary tumor < 5 cm, HBV-related (HbsAg+/anti-HCV-) HCC were eligible. Accruals were stratified by HBV genotype (C vs. non-C) and serum viral titer ( < 20,000 vs. > 20,000 IU/mL) and randomly assigned to receive either 3 years of adeforvir treatment from study entry or observation alone, in which 18 months of lamivudine would be given when their HBV DNA titer > 20,000 IU/mL and ALT > 2.0 x UNL. The primary endpoint was late RFS. Results: Between April 2007 and August 2010 (early terminated because lamivudine was no longer the standard care for chronic HBV infection), a total of 117 patients were enrolled. The demographic characteristics were well-balanced between adefovir (N = 58) and control (N = 59) arms. At a median follow-up of 57.9 months, 53 (45.3%) had recurrence and 17 (14.5%) were deceased. The cumulative 5-year FRS and OS rates of ITT cohort were 52.6% and 86.4%, respectively. The median RFS were not reached yet in adefovir arm and 6.4 years in control arm; while the 5-year RFS rate in corresponding arm was 53.8% (95% confidence interval [CI], 38.8% to 66.6%) and 51.6% (95% CI, 37.4% to 64.0%), respectively (P = 0.692, log-rank test). In Cox’s regression univariate analysis, only baseline HBeAg and HBV DNA titer significantly affected RFS, with a HR of 2.988 (95% CI: 1.489 - 5.994, p = 0.0021) and 1.916 (95% CI: 1.083 - 3.388, p = 0.0255), respectively. Late RFS in those with RFS > 2 years was also similar between two study arms. Conclusions: Despite earlier trials showed adjuvant anti-HBV nucleoside (vs. no treament) can significantly improve the RFS and OS in post-operative HBV-related HCC (JCO 2013 and Ann Surg 2015). In current study, 3 years of adjuvant adeforvir did not reduce the postoperative recurrence as well as late recurrence of HBV-related HCC as compared to observation followed by lamivudine when their HBV DNA titer > 20,000 IU/mL and ALT > 2.0 x UNL.
    日期: 2015-05
    關聯: Journal of Clinical Oncology. 2015 May;33(15, Suppl.):4101.
    Link to: http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/4101
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0732-183X&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000358036900939
    顯示於類別:[陳立宗] 會議論文/會議摘要
    [蕭金福] 會議論文/會議摘要

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    ISI000358036900939.pdf57KbAdobe PDF618檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋